Director Torsten Kreindl of SiTime Corp filed a Form 4 on August 18, 2026, disclosing two open-market sales of SiTime common stock executed on August 14 and August 17, 2026.
A Form 4 filed with the SEC on August 18, 2026 discloses that Dwight A. Merriman, a director of MongoDB, Inc. (NASDAQ:MDB), sold shares of the company's common stock on August 14 and August 17, 2026, pursuant to a Rule 10b5-1 trading plan.
Mary C. Scherer, Chief Accounting Officer of Cardinal Health Inc, filed a statement of changes in beneficial ownership on August 18, 2026, reporting transactions in Cardinal Health common shares dated August 15, 2026.
A Form 4 filed on August 18, 2026 with the U.S. Securities and Exchange Commission discloses that Brittany Hankamer, Executive Vice President and Chief HR Officer of Avantor, Inc. (NYSE:AVTR), had 181 shares of common stock withheld by the issuer on August 14, 2026 …
Valerie Christine Pitteroff, Chief Human Resources Officer of Cardinal Health Inc (NYSE:CAH), filed a Form 4 on August 18, 2026, disclosing two transactions in common shares dated August 15, 2026.
Christopher C. Ferraro, President and Chief Investment Officer of Galaxy Digital Inc., filed a Form 4 on August 18, 2026, reporting the exercise of 50,000 stock options and the resulting acquisition of Class A Common Stock.
Deborah Weitzman, CEO of Cardinal Health Inc's PSS Segment, filed a Form 4 on August 18, 2026, disclosing two transactions in Cardinal Health common shares dated August 15, 2026.
Bryan Michael Hanson, Executive Vice President of Global Portfolio Management and Marketing at QuidelOrtho Corp (NASDAQ:QDEL), filed a Form 4 on August 18, 2026, reporting transactions in common stock on August 15, 2026.
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc (NASDAQ:CORT), filed a Form 4 on August 18, 2026, disclosing two transactions in common stock dated August 17, 2026: a gift of 125 shares and an open-market sale of 10,000 shares.
Director James N. Wilson filed a Form 4 with the SEC on August 18, 2026, disclosing the sale of 10,000 shares of Corcept Therapeutics common stock on August 14, 2026, executed under a pre-established 10b5-1 trading plan.